NanoViricides Has Completed The Single-ascending Dose Part Of The Phase 1A/1B Human Trial Of NV-COV-2, A Broad-spectrum Antiviral Drug, Recruitment For The Multiple-ascending Dose Part Was Also Completed
NanoViricides Has Completed The Single-ascending Dose Part Of The Phase 1A/1B Human Trial Of NV-COV-2, A Broad-spectrum Antiviral Drug, Recruitment For The Multiple-ascending Dose Part Was Also Completed
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.